Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    INBRX 101
Previous Study | Return to List | Next Study

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (rhAAT-Fc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03815396
Recruitment Status : Recruiting
First Posted : January 24, 2019
Last Update Posted : October 5, 2020
Sponsor:
Information provided by (Responsible Party):
Inhibrx, Inc.

Brief Summary:
This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.

Condition or disease Intervention/treatment Phase
Alpha-1 Antitrypsin Deficiency AATD Drug: INBRX-101/rhAAT-Fc Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Actual Study Start Date : July 19, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021


Arm Intervention/treatment
Experimental: Part 1 Single Ascending Dose
INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
Drug: INBRX-101/rhAAT-Fc
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).

Experimental: Part 2 Multiple Ascending Dose
INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
Drug: INBRX-101/rhAAT-Fc
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).




Primary Outcome Measures :
  1. Frequency of adverse events of INBRX-101 [ Time Frame: Up to 7 months ]
    Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.

  2. Severity of adverse events of INBRX-101 [ Time Frame: Up to 7 months ]
    Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.


Secondary Outcome Measures :
  1. Area under the serum concentration time curve (AUC) of INBRX-101 [ Time Frame: Up to 7 months ]
    Area under the serum concentration time curve (AUC) of INBRX-101 will be determined.

  2. Maximum observed serum concentration (Cmax) of INBRX-101 [ Time Frame: Up to 7 months ]
    Maximum observed serum concentration (Cmax) of INBRX-101 will be determined.

  3. Trough observed serum concentration (Ctrough) of INBRX-101 [ Time Frame: Up to 7 months ]
    Trough observed serum concentration (Cmax) of INBRX-101 will be determined.

  4. Time to Cmax (Tmax) of INBRX-101 [ Time Frame: Up to 7 months ]
    Time to Cmax (Tmax) of INBRX-101 will be determined.

  5. Half-life (T1/2) of INBRX-101 [ Time Frame: Up to 7 months ]
    Half-life of INBRX-101 will be determined.

  6. Immunogenicity of INBRX-101 [ Time Frame: Up to 7 months ]
    Frequency and consequences of anti-drug antibodies (ADA) against INBRX-101 will be determined.

  7. Distribution of INBRX-101 in Bronchoalveolar Lavage Fluid (BALF) [ Time Frame: Up to 7 months ]
    The concentration of INBRX-101 in bronchoalveolar lavage fluid (BALF) be determined.

  8. Functional concentration of INBRX-101 in serum and BALF [ Time Frame: Up to 7 months ]
    The functional concentration of INBRX-101 in serum and BALF will be determined.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented alpha-1 antitrypsin (AAT) serum concentration <11 μM.
  • Diagnosis of alpha-1 antitrypsin deficiency (AATD) with any allelic combination with exception of the null/null genotype.
  • For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: post-bronchodilator FEV1 of at least 40% of predicted normal value.
  • For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: subjects eligible for bronchoscopy per judgment of investigator.
  • Nonsmoker for at least 6 months prior to study and must remain nonsmoking for the entire study duration.
  • Adequate hepatic and renal function as defined per protocol.
  • Willing to undergo current augmentation therapy washout (if applicable) and refrain from initiating augmentation therapy, other investigational drug trials for AATD, therapy with IV immunoglobulins or monoclonal antibodies during the entire study, including follow-up.

Exclusion Criteria:

  • Known or suspected allergy to components of INBRX-101 (AAT or human IgG) or pdAAT.
  • Participation in any investigational drug trial within 30 days prior to this trial, or subjects receiving IV immunoglobulins or monoclonal antibodies within 30 days prior to this trial.
  • History of and/or on the waiting list for lung or liver transplant, lobectomy, or lung volume reduction surgery.
  • Acute respiratory tract infection or COPD exacerbation that required antibiotic treatment and/or increase in systemic steroid dosage within the 4 weeks prior to screening. Subjects are permitted to continue to receive steroids if the investigator judges the subject to have a history of stable dosing.
  • Subjects with ongoing or history of unstable cor pulmonale.
  • Infection with hepatitis A, B, or C or human immunodeficiency virus (HIV).
  • Active autoimmune disease or documented history of autoimmune disease that 1) required systemic steroids or immune-suppressive medications and 2) tested positive for auto-antibodies. Exception: Endocrinopathies managed with hormone replacement therapy (HRT).
  • Current substance and/or alcohol abuse with protocol defined exceptions.
  • Current narcotics abuse with protocol defined exceptions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03815396


Contacts
Layout table for location contacts
Contact: Rebecca Penninga, ClinMgr 858-500-7833 clinicaltrials@inhibrx.com

Locations
Layout table for location information
United States, California
UC Davis School of Medicine Not yet recruiting
Sacramento, California, United States, 95817
Contact: Tina Tham    916-734-3351    ttham@ucdavis.edu   
Principal Investigator: Brooks Kuhn, MD         
United States, Florida
University of Florida College of Medicine Recruiting
Gainesville, Florida, United States, 32611
Contact: Jesse West    866-229-6312    Jesse.west@medicine.ufl.edu   
Principal Investigator: Mark Brantly, MD         
University of Miami Recruiting
Miami, Florida, United States, 33125
Contact: Patricia Rebolledo    305-243-2568    prebolledo@med.miami.edu   
Principal Investigator: Michael Campos, MD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Stephanie Fritz    317-274-4363    safritz@iu.edu   
Principal Investigator: Cynthia Brown, MD         
United States, Missouri
Hannibal Clinic Recruiting
Hannibal, Missouri, United States, 63401
Contact: Humam Farah, MD    314-341-7646      
United States, Pennsylvania
Temple University Hospital Not yet recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Sylvia Johnson    215-707-4679    Sylvia.Johnson@tuhs.temple.edu   
Principal Investigator: Friedrich Kueppers, MD         
United States, Texas
The University of Texas Health Science Center at Tyler Recruiting
Tyler, Texas, United States, 75708
Contact: Rebekah Hibbard    903-877-8246      
Principal Investigator: Megan Devine, MD         
New Zealand
The New Zealand Respiratory and Sleep Institute Not yet recruiting
Auckland, New Zealand
Contact: Fay Sommerville    64 9 638 5255      
Principal Investigator: Andrew Veale, MD         
Christchurch Clinical Studies Trust Ltd Not yet recruiting
Christchurch, New Zealand
Contact: James Swan    64 3 372947      
Principal Investigator: Alex Cole, MD         
Waikato Respiratory and Gastro Research Unit Not yet recruiting
Hamilton, New Zealand
Contact: Chris Tuffery    64 7858 0984      
Principal Investigator: Catherina Chang, MD         
United Kingdom
University of Cambridge Recruiting
Cambridge, East Of England, United Kingdom, CB2 0QQ
Contact: Jacqui Galloway    +44 (0) 1223 216279    jacqui.galloway@addenbrookes.nhs.uk   
Principal Investigator: Ravi Mahadeva, MD         
University Hospital Birmingham NHS Foundation Trust Recruiting
Birmingham, West Midlands, United Kingdom, B15 2GW
Contact: Anita Pye    +44 121 371 3886    Anita.Pye@uhb.nhs.uk   
Principal Investigator: Alice Turner, MD         
Sponsors and Collaborators
Inhibrx, Inc.
Investigators
Layout table for investigator information
Study Director: Klaus Wagner, MD, PhD CMO
Layout table for additonal information
Responsible Party: Inhibrx, Inc.
ClinicalTrials.gov Identifier: NCT03815396    
Other Study ID Numbers: Ph1 INBRX-101
First Posted: January 24, 2019    Key Record Dates
Last Update Posted: October 5, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Inhibrx, Inc.:
Alpha-1 antitrypsin deficiency
AATD
alpha-1 disease
AAT
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Emphysema
Pathologic Processes